FI964565A0 - Menetelmiä antihistamiinisten piperidiinijohdosten vedettömien ja hydratoituneiden muotojen, niiden polymorfien ja pseudomorfien, valmistamiseksi - Google Patents

Menetelmiä antihistamiinisten piperidiinijohdosten vedettömien ja hydratoituneiden muotojen, niiden polymorfien ja pseudomorfien, valmistamiseksi

Info

Publication number
FI964565A0
FI964565A0 FI964565A FI964565A FI964565A0 FI 964565 A0 FI964565 A0 FI 964565A0 FI 964565 A FI964565 A FI 964565A FI 964565 A FI964565 A FI 964565A FI 964565 A0 FI964565 A0 FI 964565A0
Authority
FI
Finland
Prior art keywords
pseudomorphs
polymorphs
methods
hydrated forms
piperidine derivatives
Prior art date
Application number
FI964565A
Other languages
English (en)
Swedish (sv)
Other versions
FI964565A (fi
Inventor
Daniel R Henton
Frederick J Mccarty
Susan I Tripp
Jill E Dewitt
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26937420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI964565(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Publication of FI964565A0 publication Critical patent/FI964565A0/fi
Publication of FI964565A publication Critical patent/FI964565A/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Peptides Or Proteins (AREA)
FI964565A 1994-05-18 1996-11-14 Menetelmiä antihistamiinisten piperidiinijohdosten vedettömien ja hydratoituneiden muotojen, niiden polymorfien ja pseudomorfien, valmistamiseksi FI964565A (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24573194A 1994-05-18 1994-05-18
US41716195A 1995-04-11 1995-04-11
PCT/US1995/004942 WO1995031437A1 (en) 1994-05-18 1995-04-28 Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof

Publications (2)

Publication Number Publication Date
FI964565A0 true FI964565A0 (fi) 1996-11-14
FI964565A FI964565A (fi) 1996-11-14

Family

ID=26937420

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964565A FI964565A (fi) 1994-05-18 1996-11-14 Menetelmiä antihistamiinisten piperidiinijohdosten vedettömien ja hydratoituneiden muotojen, niiden polymorfien ja pseudomorfien, valmistamiseksi

Country Status (18)

Country Link
US (12) US20010014741A1 (fi)
EP (3) EP1178041A1 (fi)
JP (7) JPH10500134A (fi)
CN (3) CN1148849A (fi)
AT (1) ATE220667T1 (fi)
AU (1) AU693892B2 (fi)
CA (3) CA2449419C (fi)
DE (1) DE69527429T2 (fi)
DK (1) DK0766668T3 (fi)
ES (1) ES2176329T3 (fi)
FI (1) FI964565A (fi)
HK (2) HK1098467A1 (fi)
HU (1) HU227676B1 (fi)
IL (3) IL134917A (fi)
MX (1) MX9605613A (fi)
NO (1) NO315319B1 (fi)
PT (1) PT766668E (fi)
WO (1) WO1995031437A1 (fi)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9400555D0 (en) * 1994-01-13 1994-03-09 Short Brothers Plc Boundery layer control in aerodynamic low drag structures
CA2449419C (en) * 1994-05-18 2011-09-06 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
MX9706449A (es) * 1995-02-28 1997-11-29 Hoechst Marion Roussel Inc Composicion farmaceutica para compuestos de piperidinalcanol.
BR9812001A (pt) * 1997-08-26 2000-09-26 Hoechst Marion Roussel Inc Composição farmacêutica para combinação de descongestionante piperidinoalcanol
IN191492B (fi) * 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
US6613906B1 (en) * 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
CH695216A5 (de) 2001-02-23 2006-01-31 Cilag Ag Verfahren zur Herstellung eines nicht hydratisierten Salzes eines Piperidinderivats und eine so erhältliche neue kristalline Form eines solchen Salzes.
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
AU2002305162A1 (en) * 2001-04-09 2002-10-21 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
IL159266A0 (en) * 2001-06-18 2004-06-01 Reddys Lab Ltd Dr Crystalline forms of fexofenadine and processes for the preparation thereof
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
ES2301662T3 (es) * 2001-07-31 2008-07-01 Texcontor Etablissement Polimorfo de clorhidrato de fexofenadina.
US20030158227A1 (en) * 2001-11-08 2003-08-21 Barnaba Krochmal Polymorphs of fexofenadine base
AU2003248657A1 (en) * 2002-06-10 2003-12-22 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
JP3910907B2 (ja) * 2002-10-29 2007-04-25 新光電気工業株式会社 キャパシタ素子及びこの製造方法、半導体装置用基板、並びに半導体装置
CA2530193A1 (en) 2003-07-03 2005-01-20 Teva Pharmaceutical Industries Ltd. Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
CA2560882A1 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
EP1616861A3 (en) * 2004-06-15 2006-02-08 Dipharma S.p.A. A process for the preparation of keto compounds
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
US20060148851A1 (en) * 2004-09-28 2006-07-06 Shlomit Wizel Fexofenadine crystal form and processes for its preparation thereof
DOP2006000274A (es) * 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
KR20090037930A (ko) * 2006-07-11 2009-04-16 뮤추얼 파마슈티컬 컴퍼니 아이엔씨. 조절 방출 제형
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
US20090306135A1 (en) 2008-03-24 2009-12-10 Mukesh Kumar Sharma Stable amorphous fexofenadine hydrochloride
US20100183717A1 (en) * 2009-01-16 2010-07-22 Kristin Arnold Controlled-release formulations
CN102595879B (zh) 2009-11-06 2014-08-06 巴斯夫欧洲公司 4-羟基苯甲酸和选定农药的结晶配合物
ES2403130B1 (es) 2010-06-15 2014-09-29 Chemelectiva S.R.L. Forma polimórfica de clorhidrato de fexofenadina, compuestos intermedios y procedimiento para su preparación
IT1400965B1 (it) 2010-06-15 2013-07-05 Dipharma Francis Srl Polimorfi di fexofenadina
US9420872B2 (en) * 2010-08-23 2016-08-23 Jason Bird Apparatus and system for holding game-calling devices
JP2012087100A (ja) * 2010-10-21 2012-05-10 Sumitomo Chemical Co Ltd 形態ｉのフェキソフェナジン一塩酸塩の製造方法
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US631375A (en) * 1899-04-12 1899-08-22 Ephraim Musselman Face-protector.
US3448152A (en) * 1966-11-03 1969-06-03 Jefferson Chem Co Inc Amine recovery
US3965257A (en) 1972-01-28 1976-06-22 Richardson-Merrell Inc. Compositions and methods for the treatment of the symptoms of histamine induced allergic reactions
BE794598A (fr) 1972-01-28 1973-05-16 Richardson Merrell Inc Nouveaux derives olefiniques de piperidines substituees en 4 et leur procede de preparation
US3878217A (en) * 1972-01-28 1975-04-15 Richardson Merrell Inc Alpha-aryl-4-substituted piperidinoalkanol derivatives
US4254130A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285958A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285957A (en) * 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
IL63968A (en) 1980-10-01 1985-10-31 Glaxo Group Ltd Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it
US4742175A (en) 1986-05-07 1988-05-03 Merrell Dow Pharmaceuticals Inc. Preparation of polymorphically pure terfenadine
JPH02213431A (ja) * 1989-02-13 1990-08-24 Kobe Steel Ltd ＳｉＣウィスカ強化Ａｌ合金複合材料
DE4034218A1 (de) 1990-10-27 1992-04-30 Merck Patent Gmbh Verfahren zur herstellung von carebastin
TW198008B (fi) 1991-04-08 1993-01-11 Green Cross Corp
US5631375A (en) * 1992-04-10 1997-05-20 Merrell Pharmaceuticals, Inc. Process for piperidine derivatives
DE69332117T2 (de) 1992-04-10 2003-01-30 Merrell Pharmaceuticals Inc., Cincinnati 4-diphenylmethylpiperidine und verfahren zu ihrer herstellung
ATE194913T1 (de) 1992-05-11 2000-08-15 Merrell Pharma Inc Verwendung von terfenadin-derivaten als antihistaminika in leberkranken patienten
EP0701443B2 (en) 1992-08-03 2000-11-22 Sepracor, Inc. Terfenadine metabolites and their optically pure isomers for treating allergic disorders
US5315016A (en) 1992-10-13 1994-05-24 Nycomed Dak A/S Process for preparing pure podophyllotoxin
CA2181089C (en) 1993-06-24 2000-05-23 Thomas E. D'ambra Piperidine derivatives and process for their production
KR100387348B1 (ko) 1993-06-24 2003-06-12 알바니 몰레큘라 리써치, 인크. 피페리딘 유도체의 제조 방법
CA2166059C (en) 1993-06-25 2005-08-16 Richard Carl Krauss Novel intermediates for the preparation of antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives
US6147216A (en) 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
CA2449419C (en) * 1994-05-18 2011-09-06 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US5576610A (en) 1994-07-05 1996-11-19 Motorola, Inc. Method and apparatus for determining battery characteristics
IL134770A (en) 1995-02-28 2002-02-10 Aventis Pharma Inc Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form
MX9706449A (es) * 1995-02-28 1997-11-29 Hoechst Marion Roussel Inc Composicion farmaceutica para compuestos de piperidinalcanol.
US5574045A (en) * 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
BR9812001A (pt) * 1997-08-26 2000-09-26 Hoechst Marion Roussel Inc Composição farmacêutica para combinação de descongestionante piperidinoalcanol
US6214427B1 (en) * 1998-08-28 2001-04-10 General Electric Company Method of making an electronic device having a single crystal substrate formed by solid state crystal conversion
US6613906B1 (en) 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
US20020177680A1 (en) * 2000-08-23 2002-11-28 Hubbell Jeffrey A. Novel polymer compounds
US6475942B1 (en) * 2000-09-05 2002-11-05 General Electric Company Conversion of polycrystalline alumina to single crystal sapphire using molybdenum doping
AU2002305162A1 (en) * 2001-04-09 2002-10-21 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US7700779B2 (en) * 2001-06-18 2010-04-20 Dr. Reddy's Laboratories Limited Crystalline forms of fexofenadine and its hydrochloride
US20090211514A1 (en) * 2008-02-26 2009-08-27 Lehigh University Single crystal conversion process

Also Published As

Publication number Publication date
US20040014976A1 (en) 2004-01-22
JP2010120969A (ja) 2010-06-03
CA2585705C (en) 2012-04-17
US7666881B2 (en) 2010-02-23
MX9605613A (es) 1998-05-31
HU9603167D0 (en) 1997-01-28
CN1907967B (zh) 2012-07-04
AU693892B2 (en) 1998-07-09
EP0766668B1 (en) 2002-07-17
IL134917A0 (en) 2001-05-20
JPH10500134A (ja) 1998-01-06
JP4503907B2 (ja) 2010-07-14
US20020193603A1 (en) 2002-12-19
HUT76134A (en) 1997-06-30
CA2449419C (en) 2011-09-06
ATE220667T1 (de) 2002-08-15
CA2449419A1 (en) 1995-11-23
JP4503908B2 (ja) 2010-07-14
IL113747A0 (en) 1995-08-31
US7135571B2 (en) 2006-11-14
HK1098467A1 (en) 2007-07-20
CN1907967A (zh) 2007-02-07
DE69527429D1 (de) 2002-08-22
EP1178041A1 (en) 2002-02-06
PT766668E (pt) 2002-11-29
AU2426595A (en) 1995-12-05
EP0766668A1 (en) 1997-04-09
HK1137742A1 (en) 2010-08-06
CA2189007A1 (en) 1995-11-23
US20010025106A1 (en) 2001-09-27
US20020193601A1 (en) 2002-12-19
US20080167471A1 (en) 2008-07-10
HU227676B1 (en) 2011-11-28
US20020193600A1 (en) 2002-12-19
US20010012896A1 (en) 2001-08-09
JP2002255936A (ja) 2002-09-11
DE69527429T2 (de) 2003-03-20
NO964859L (no) 1996-11-15
CA2189007C (en) 2004-03-02
EP2354125A1 (en) 2011-08-10
JP2002308849A (ja) 2002-10-23
CN1623985A (zh) 2005-06-08
FI964565A (fi) 1996-11-14
US20010014741A1 (en) 2001-08-16
CA2585705A1 (en) 1995-11-23
CN1148849A (zh) 1997-04-30
US20030045721A1 (en) 2003-03-06
JP4503909B2 (ja) 2010-07-14
ES2176329T3 (es) 2002-12-01
IL134917A (en) 2001-07-24
WO1995031437A1 (en) 1995-11-23
JP2002308850A (ja) 2002-10-23
US20080167469A1 (en) 2008-07-10
IL113747A (en) 2001-05-20
US7138524B2 (en) 2006-11-21
US20070021462A1 (en) 2007-01-25
US20070021461A1 (en) 2007-01-25
NO315319B1 (no) 2003-08-18
DK0766668T3 (da) 2002-10-28
JP2002255935A (ja) 2002-09-11
NO964859D0 (no) 1996-11-15
JP2002316978A (ja) 2002-10-31
US7662835B2 (en) 2010-02-16

Similar Documents

Publication Publication Date Title
FI964565A0 (fi) Menetelmiä antihistamiinisten piperidiinijohdosten vedettömien ja hydratoituneiden muotojen, niiden polymorfien ja pseudomorfien, valmistamiseksi
DE69709938D1 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
NO304071B1 (no) Heterocyklisk-cykliske amin-derivater
NO932870D0 (no) Ny fremgangsmaate for fremstilling av 9-amino-6-demetyl-6-deoksyetracykliner
FI914905A (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten merkaptoasetyyliamidopyrrolo- ja -pyridobentsatsepiinijohdannaisten valmistamiseksi
KR900700486A (ko) 신규한 벤조피리도 피페리딘, 피페리딜리덴 및 피페라진 화합물, 조성물, 제조방법 및 이용방법
DE69401817D1 (de) Verbesserungen zum herstellen von glasartigem silika
HU9301362D0 (en) Method for producing 4-aryl-piperazines and 4-aryl-piperidines
DK543787D0 (da) Antibakterielle midler
FI952148A0 (fi) Geenitekninen menetelmä ja isäntä ksylitolin valmistamiseksi
TW362096B (en) Novel piperidine derivatives and the process for preparing the same
FI101376B1 (fi) Menetelmä 3-bentsyyliamino-2-fenyylipiperidiinijohdannaisten valmistamiseksi
ES2108004T3 (es) Nuevas alquil piperidinas sustituidas y su empleo como inhibidores de la sintesis de colesterol.
ATE169909T1 (de) Benzyl- und benzhydryl alkohole
NO995132D0 (no) Fremgangsmåte for reduksjon av fibrinogen